传统及新型调脂药物在非酒精性脂肪性肝病治疗中的价值
Application of lipid-modulating drugs in treatment of non-alcoholic fatty liver disease
摘要
非酒精性脂肪性肝病(non-alcoholic fatty liver disease,NAFLD)是目前最常见的肝脏疾病,其疾病谱包括非酒精性肝脂肪变(non-alcoholic hepatic steatosis,NAS)、非酒精性脂肪性肝炎(non-alcoholic steatohepatitis,NASH)、肝硬化和肝细胞性肝癌(hepatocellular carcinoma,HCC)[1]。
作者
张瑞祥
孙烁烁
韦晓
刘超
ZHANG Ruixiang;SUN Shuoshuo;WEI Xiao
出处
《内科理论与实践》
2023年第3期215-220,共6页
Journal of Internal Medicine Concepts & Practice
参考文献2
-
1Eugene Chang,Lisa Kim,Se Eun Park,Eun-Jung Rhee,Won-Young Lee,Ki-Won Oh,Sung-Woo Park,Cheol-Young Park.Ezetimibe improves hepatic steatosis in relation to autophagy in obese and diabetic rats[J].World Journal of Gastroenterology,2015,21(25):7754-7763. 被引量:4
-
2Yun-Hua Li,Lu-Hua Yang,Kai-Hui Sha,Tong-Gang Liu,Li-Guo Zhang,Xian-Xian Liu.Efficacy of poly-unsaturated fatty acid therapy on patients with nonalcoholic steatohepatitis[J].World Journal of Gastroenterology,2015,21(22):7008-7013. 被引量:2
二级参考文献52
-
1Marko Duvnjak,Ivan Leroti,Neven Bari,Vedran Tomai,Lucija Virovi Juki,Vedran Velagi.Pathogenesis and management issues for non-alcoholic fatty liver disease[J].World Journal of Gastroenterology,2007,13(34):4539-4550. 被引量:75
-
2Clark JM. The epidemiology of nonalcoholic fatty liver diseasein adults. J Clin Gastroenterol 2006; 40 Suppl 1: S5-10 [PMID:16540768 DOI: 10.1097/01.mcg.0000168638.84840.ff].
-
3Lazo M, Clark JM. The epidemiology of nonalcoholic fatty liverdisease: a global perspective. Semin Liver Dis 2008; 28: 339-350[PMID: 18956290 DOI: 10.1055/s-0028-1091978].
-
4Browning JD, Szczepaniak LS, Dobbins R, Nuremberg P, HortonJD, Cohen JC, Grundy SM, Hobbs HH. Prevalence of hepaticsteatosis in an urban population in the United States: impact ofethnicity. Hepatology 2004; 40: 1387-1395 [PMID: 15565570 DOI:10.1002/hep.20466].
-
5Byrne CD. Dorothy Hodgkin Lecture 2012: non-alcoholic fatty liverdisease, insulin resistance and ectopic fat: a new problem in diabetesmanagement. Diabet Med 2012; 29: 1098-1107 [PMID: 22672330DOI: 10.1111/j.1464-5491.2012.03732.x].
-
6Altmann SW, Davis HR, Zhu LJ, Yao X, Hoos LM, Tetzloff G, IyerSP, Maguire M, Golovko A, Zeng M, Wang L, Murgolo N, GrazianoMP. Niemann-Pick C1 Like 1 protein is critical for intestinalcholesterol absorption. Science 2004; 303: 1201-1204 [PMID:14976318 DOI: 10.1126/science.1093131].
-
7Garcia-Calvo M, Lisnock J, Bull HG, Hawes BE, Burnett DA,Braun MP, Crona JH, Davis HR, Dean DC, Detmers PA, GrazianoMP, Hughes M, Macintyre DE, Ogawa A, O'neill KA, Iyer SP,Shevell DE, Smith MM, Tang YS, Makarewicz AM, UjjainwallaF, Altmann SW, Chapman KT, Thornberry NA. The target ofezetimibe is Niemann-Pick C1-Like 1 (NPC1L1). Proc Natl AcadSci USA 2005; 102: 8132-8137 [PMID: 15928087 DOI: 10.1073/pnas.0500269102].
-
8Deushi M, Nomura M, Kawakami A, Haraguchi M, Ito M, OkazakiM, Ishii H, Yoshida M. Ezetimibe improves liver steatosis andinsulin resistance in obese rat model of metabolic syndrome. FEBSLett 2007; 581: 5664-5670 [PMID: 18022391 DOI: 10.1016/j.febslet.2007.11.023].
-
9Nomura M, Ishii H, Kawakami A, Yoshida M. Inhibition of hepaticNiemann-Pick C1-like 1 improves hepatic insulin resistance. AmJ Physiol Endocrinol Metab 2009; 297: E1030-E1038 [PMID:19654286 DOI: 10.1152/ajpendo.00343.2009].
-
10Takase H, Dohi Y, Okado T, Hashimoto T, Goto Y, Kimura G.Effects of ezetimibe on visceral fat in the metabolic syndrome: arandomised controlled study. Eur J Clin Invest 2012; 42: 1287-1294[PMID: 23033884 DOI: 10.1111/eci.12000].
共引文献4
-
1朱国英,黄东平,黄建伟,杨长青,朱风尚.ω-3多不饱和脂肪酸联合膳食营养对非酒精性脂肪性肝病患者的影响[J].同济大学学报(医学版),2017,38(2):79-83. 被引量:5
-
2周岐鸣,刘洋,季光,宋海燕.调节自噬改善非酒精性脂肪性肝病的药物研究进展[J].中华中医药学刊,2018,36(10):2463-2467. 被引量:5
-
3Katherine Byrnes,Sophia Blessinger,Niani Tiaye Bailey,Russell Scaife,Gang Liu,Bilon Khambu.Therapeutic regulation of autophagy in hepatic metabolism[J].Acta Pharmaceutica Sinica B,2022,12(1):33-49. 被引量:13
-
4高淑君,张浩,武沐洋,张新月,肖培伦,王晓莉,王凡涛.低氧预处理人牙髓干细胞对缺氧缺血性脑损伤新生大鼠脑神经元自噬及ATG7的影响[J].中国儿童保健杂志,2023,31(8):851-857.
-
1刘媛,胡筱燕.依折麦布治疗冠心病的疗效及对患者心功能的影响[J].中文科技期刊数据库(全文版)医药卫生,2023(5):59-62.
-
2谢欢,陈绚,韦维,谭皓文.临床药师主导的慢性病管理对改善脑卒中患者临床指标及生命质量的影响[J].临床合理用药杂志,2023,16(17):128-130. 被引量:1
-
3李世军,李小鹰.高龄老年血脂代谢紊乱的管理新进展[J].中华老年心脑血管病杂志,2023,25(4):433-437. 被引量:1
-
4罗德宝.多学科协作联合延续性护理对非酒精性脂肪肝患者血脂及自我管理行为的影响[J].中外医药研究,2023,2(4):92-94.
-
5吕凤芹,徐象珍,吕海燕,马春玲,陈彬彬.基于治疗药物监测的奥氮平片2个集采批次的临床应用分析[J].中国合理用药探索,2023,20(5):106-110.
-
6吴振.心肌梗死后射血分数下降患者应用沙库巴曲缬沙坦钠治疗的临床疗效评估[J].现代诊断与治疗,2023,34(6):848-851.
-
7张磊.阿托伐他汀治疗血脂异常症[J].肝博士,2023(4):50-51.
-
8刘楚.多烯磷脂酰胆碱联合还原型谷胱甘肽治疗非酒精性脂肪性肝炎的效果研究[J].中文科技期刊数据库(全文版)医药卫生,2023(8):98-101.
-
9曾伟兰,汪艳.内质网应激与非酒精性脂肪性肝病肝损伤[J].肝脏,2023,28(6):633-636.
-
10尹会芬,于红艳,刘志平.非酒精性脂肪性肝病合并2型糖尿病患者血清瘦素、视黄醇结合蛋白4和胆碱酯酶水平变化及其临床意义研究[J].实用肝脏病杂志,2023,26(4):500-503.